CN111073972B - Application of MYH6 gene in congenital heart disease diagnosis product - Google Patents
Application of MYH6 gene in congenital heart disease diagnosis product Download PDFInfo
- Publication number
- CN111073972B CN111073972B CN201910735518.2A CN201910735518A CN111073972B CN 111073972 B CN111073972 B CN 111073972B CN 201910735518 A CN201910735518 A CN 201910735518A CN 111073972 B CN111073972 B CN 111073972B
- Authority
- CN
- China
- Prior art keywords
- myh6
- gene
- mutation
- product
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150107698 MYH6 gene Proteins 0.000 title claims abstract description 28
- 208000002330 Congenital Heart Defects Diseases 0.000 title claims abstract description 26
- 208000028831 congenital heart disease Diseases 0.000 title claims abstract description 26
- 238000003745 diagnosis Methods 0.000 title abstract description 11
- 101000958741 Homo sapiens Myosin-6 Proteins 0.000 claims abstract description 35
- 102100038319 Myosin-6 Human genes 0.000 claims abstract description 33
- 230000035772 mutation Effects 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 230000014509 gene expression Effects 0.000 claims abstract description 16
- 239000000523 sample Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 7
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 210000004789 organ system Anatomy 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 26
- 238000003018 immunoassay Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 208000013914 atrial heart septal defect Diseases 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000001605 fetal effect Effects 0.000 description 6
- 238000007901 in situ hybridization Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 238000007480 sanger sequencing Methods 0.000 description 5
- 206010064571 Gene mutation Diseases 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000002583 angiography Methods 0.000 description 4
- 230000001746 atrial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 238000007482 whole exome sequencing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 108091005975 Myofilaments Proteins 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003632 microfilament Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000003699 striated muscle Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 101150070366 2C gene Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000035478 Interatrial communication Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010003664 atrial septal defect Diseases 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 102000056087 human MYH6 Human genes 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000003365 myofibril Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000003287 Eisenmenger Complex Diseases 0.000 description 1
- 208000020686 Eisenmenger syndrome Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 206010053652 Limb deformity Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 101710204027 Myosin-6 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical group CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- JZBRFIUYUGTUGG-UHFFFAOYSA-J tetrapotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].[K+].[K+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JZBRFIUYUGTUGG-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides an application of a MYH6 gene in a congenital heart disease diagnosis product, and particularly relates to an application of a MYH6 gene, an expression level of the MYH6 gene, a MYH6 mutant gene or a mutation of an expression product of the MYH6 gene in a congenital heart disease diagnosis product; the invention also provides a congenital heart disease model, and further proves the relationship between the MYH6 gene and the congenital heart disease through experiments.
Description
Technical Field
The invention relates to the field of gene application, in particular to application of a MYH6 gene in a congenital heart disease diagnosis product.
Background
Congenital Heart Disease (CHD) refers to heart and large blood vessels that exhibit abnormal anatomical structures after birth due to abnormal occurrence and development of the heart and large blood vessels during embryonic development. CHD is the most common birth defect in China at present, has the morbidity of about 0.6-0.8 percent and accounts for 1/5-1/4 of all birth defects. CHD not only causes physical and psychological pains to patients, but also causes great economic stress and social burden to families and society.
Atrial Septal Defects (ASD) are the most common congenital heart disease, accounting for about one-fourth of the incidence of CHD. Among them, secondary foramen atrial septal defect (ASD ii) is one of the most common types of ASD. ASDII defects are generally located within the fossa ovalis and manifest as persistent secondary atrial openings. Normal left atrial pressure (8-10 mmHg) is slightly higher than the right atrium (3-5 mmHg). Blood is shunted from left to right through the atrial septal defect. Shunting results in an increase in right ventricular volume loading, resulting in enlargement of the right atrium, right ventricle, and pulmonary artery dilation. In the early stage of pulmonary arteriolar spasm, cells of the wall of the pulmonary arteriolar gradually proliferate and the wall of the pulmonary arteriolar gradually thickens with the lapse of time to form resistance pulmonary hypertension. When the right atrial pressure is higher than the left atrium, blood is shunted from right to left, causing cyanosis, i.e., eisenmenger syndrome. Asdii can develop in isolation, can coexist with other intracardiac malformations, and can be included in the syndrome.
The MYH6 gene encodes the Myosin-6 protein within the myocardial sarcomere (myocardial heavy chain protein. Alpha.). MYH6 protein structurally comprises a head motor domain (1-780 AA), which binds to actin protein and has Mg2+ -ATPase activity; a neck region (781-840 AA); a rod-shaped tail region (841-1938 AA). The current research shows that MYH6 gene mutation is related to more serious diseases such as dilated cardiomyopathy, hypertrophic cardiomyopathy and sick sinus syndrome besides ASD, and MYH6 mutation causing the serious diseases is mainly located in the head region, while a series of pathogenic mutations related to ASD II are mostly located in the tail region.
Fetal cardiac ultrasound is currently commonly used for fetal CHD diagnosis. However, during fetal life, the secondary interatrial foramen is continuously open, and thus asdii can only be diagnosed after birth. Some fetal patients with clinical syndromes, particularly cardiomyopathy, mental retardation, critical limb deformities, etc., are highly suspected and, if they can be detected early in the fetus, can take early steps to perform cardiac surgery during the fetal period or to avoid the fetus from being born. The method has definite familial hereditary history, and can also adopt means such as test tube babies and the like according to the detection result of parents to block the next generation of hereditary same diseases. Furthermore, it would be of great interest for MYH6 mutations to determine early if they are associated with ASD or cardiomyopathy.
The three points all provide practical requirements for the early detection, early diagnosis and differential diagnosis, early treatment and prognosis judgment of the ASDII in the fetal period. Therefore, the exploration of key molecules of ASDII has important significance in defining the molecular mechanism of atrial septal occurrence and performing auxiliary molecular diagnosis by taking the mechanism as a target, and is beneficial to early discovery, early diagnosis and early treatment.
Disclosure of Invention
An object of the present invention is to provide a gene related to CHD.
The invention also aims to provide an application of a preparation, a chip or a kit for detecting MYH6 gene, expression level of MYH6 gene, MYH6 mutant gene or mutation of MYH6 gene expression product in diagnosis of congenital heart disease.
The invention also aims to provide a cell model and application thereof in MYH6 diagnosis and treatment.
In order to achieve the purpose, the invention adopts the following technical scheme:
the MYH6 mutant gene has a nucleotide sequence shown as SEQ ID NO.1, and compared with a normal MYH6 nucleotide sequence, mutation of the nucleotide at position 1576 is changed from G to A; an expression product MYH6 mutant protein of the MYH6 mutant gene has an amino acid sequence shown in SEQ ID No.2, and compared with a normal MYH6 amino acid sequence, the amino acid sequence is changed from Glu to Lys at the 526 th site, namely the glutamic acid is mutated into lysine.
In order to analyze the relationship between CHD and MYH6 mutant genes, the invention firstly uses Sanger sequencing method to verify the mutation sites of MYH6 genes of partial congenital heart disease patients and parents thereof, and verifies the congenital heart disease by cardiac ultrasound, digital Subtraction Angiography (DSA), magnetic resonance imaging/angiography or computed tomography.
The second aspect of the invention provides for the first time the use of a MYH6 gene in a product for the detection of congenital heart disease.
Further, the product comprises a reagent for detecting MYH6 gene, expression level of MYH6 gene, MYH6 mutant gene or mutation of MYH6 gene expression product in a biological sample to detect congenital heart disease.
Further, the detection method of the product is at least one of direct nucleic acid sequencing, nucleic acid molecule hybridization technology, nucleic acid amplification technology, nucleic acid probe technology or immunodetection.
Further, the product comprises a formulation, a chip or a kit.
Further, the detection sample of the product is peripheral blood.
Further, in the nucleic acid amplification technology, primers having nucleotide sequences shown as SEQ ID NO.4 and SEQ ID NO.5 are used.
The third aspect of the invention provides a kit for diagnosing ASD, which comprises a detection reagent for specifically recognizing the 1576 th nucleotide site of the MYH6 gene or specifically recognizing and detecting the 526 th amino acid site of the MYH6 protein.
Further, the detection reagent is a probe with a nucleotide sequence shown in SEQ ID NO.3, and is complementary with nucleotides 1562-1581 in MYH6 gene (GCATTGACCTCCATCGAGAAG).
Further, the probe is SYBR Green I, taqman probe, molecular beacon, hybridization probe or composite probe
In a fourth aspect of the invention, a method of constructing an animal model of congenital heart disease is provided, wherein a MYH6 gene mutation reagent is administered to a culture system, wherein the culture system comprises a cell system, a subcellular system, a solution system, a tissue system, an organ system, or an animal system.
Further, the MYH6 gene mutation reagent is MYH6 adenovirus.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the embodiments or the description of the prior art will be briefly described below, it is obvious that the drawings in the following description are only one embodiment of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 shows the results of sequencing in a patient family;
FIG. 2 is ATPase activity of MYH 6-WT and MYH6 780-E526K;
fig. 3 is a schematic diagram of myofilament structure.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The MYH6 mutant gene comprises a MYH6 gene subjected to base substitution mutation, frame shift mutation, deletion mutation and insertion mutation, and the mutation of an expression product of the MYH6 gene comprises an expression product of the MYH6 mutant gene.
Methods for detecting expression levels of MYH6 include, but are not limited to: polymerase Chain Reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), transcription Mediated Amplification (TMA), ligase Chain Reaction (LCR), strand Displacement Amplification (SDA) and Nucleic Acid Sequence Based Amplification (NASBA), in Situ Hybridization (ISH), chromosomal microarray expression profiling, southern or Northern blotting, sandwich ELISA, radioimmunoassay (RIA), direct, indirect or contrast enzyme-linked immunosorbent assay (ELISA), enzyme Immunoassay (EIA), fluorescence Immunoassay (FIA), western blotting, immunoprecipitation, and any particle-based immunoassay (e.g. using gold, silver or latex particles, magnetic particles or quantum dots). Among them, PCR requires reverse transcription of RNA into DNA before amplification (RT-PCR), TMA and NASBA to directly amplify RNA. Detecting the expression level of a gene "refers to determining the presence of mRNA of a marker gene in a biological sample and its expression level in order to predict CHD occurrence and can be accomplished by measuring the amount of mRNA. Analytical methods for this purpose are, but are not limited to, RT-PCR, competitive RT-PCR, real-time RTPCR, RNase Protection Assay (RPA), northern blotting, DNA microarray chips, etc.
Methods for detecting gene mutations or protein mutations include, but are not limited to: PCR-SSCP method, heteroduplex analysis method, denaturation gradient gel electrophoresis method, chemical cutting mismatch method, allele specific oligonucleotide analysis method, DNA chip technology, ligase chain reaction, allele specific amplification method, direct sequencing method.
In the present invention, the formulation can determine the presence of mRNA in a sample on a test strip, membrane, chip, disk, test strip, filter, microsphere, slide, multiwell plate, or fiber optic. The assay system can have a solid support to which nucleic acids corresponding to mRNA are attached. The solid support may comprise, for example, a plastic, a silicon wafer, a metal, a resin, a glass, a membrane, a particle, a precipitate, a gel, a polymer, a flake, a sphere, a polysaccharide, a capillary, a film, a plate, or a slide. The assay components can be packaged together after manufacture as a kit for detecting mRNA.
Nucleic acid hybridization techniques of the invention include, but are not limited to, in situ hybridization (FISH), chromosomal microarrays, and Southern or Northern blots. In Situ Hybridization (FISH) is a hybridization of specific DNA or RNA sequences in a tissue section or section using a labeled complementary DNA or RNA strand as a probe (in situ) or in the entire tissue if the tissue is small enough (whole tissue embedded ISH). DNAISH can be used to determine the structure of chromosomes. Rnash is used to measure and locate mRNA and other transcripts (e.g., ncRNA) within tissue sections or whole tissue embedding. Sample cells and tissues are typically treated to fix the target transcript in situ and to increase probe access. The probe is hybridized to the target sequence at high temperature, and then excess probe is washed away. The localization and quantification of base-labeled probes in tissues labeled with radiation, fluorescence or antigens is performed using autoradiography, fluorescence microscopy or immunohistochemistry, respectively. ISH can also use two or more probes labeled with radioactive or other non-radioactive labels to detect two or more transcripts simultaneously.
In the present invention, the immunoassay can be based on any of the following methods:
immunoprecipitation (Immunoprecipitation): immunoprecipitation is the simplest immunoassay method; this method measures the amount of precipitate that is formed after the reagent antibody has been incubated with the sample and reacted with the target antigen present therein to form insoluble aggregates. The immunoprecipitation can be either qualitative or quantitative.
Particle immunoassay: in a particle immunoassay, multiple antibodies are attached to the particle and the particle is capable of binding many antigenic molecules simultaneously. This greatly accelerates the speed of the visible reaction. This allows for a fast and sensitive detection of the biomarker.
Immunoturbidimetry (immunonephelometry): in immunoturbidimetry, the interaction of the antibody and the target antigen on the biomarker causes the formation of an immune complex that is too small to precipitate. However, these complexes will scatter incident light, which can be measured using a turbidimeter. The concentration of the antigen (i.e., biomarker) can be determined within minutes of the reaction.
Radioimmunoassay (RIA): radioimmunoassays use radioisotopes such as I125 to label antigens or antibodies. The isotope used emits gamma rays, which are usually measured after removal of unbound (free) radiolabel. The main advantages of RIA compared to other immunoassays are higher sensitivity, easy signal detection and confirmation, fast assay. The main disadvantages are the health and safety risks posed by the use of radiation and the time and expense associated with maintaining licensed radiation safety and disposal procedures. For this reason, RIA has been largely replaced by enzyme immunoassays in routine clinical laboratory practice.
Enzyme Immunoassay (EIA): enzyme immunoassays use enzymes to label antibodies or target antigens. The sensitivity of EIA is close to that of RIA without the risk of being caused by radioisotopes. One of the most widely used EIA methods for detection is enzyme-linked immunosorbent assay (ELISA). The ELISA method may use two antibodies, one specific for the target antigen and the other coupled to an enzyme, the addition of an enzyme substrate causing the generation of a chemiluminescent signal or a fluorescent signal.
Fluorescence Immunoassay (FIA): fluorescence immunoassay refers to an immunoassay that uses a fluorescent label or an enzyme label that acts on a substrate to form a fluorescent product. Fluorescence measurements are inherently more sensitive than chromatic (spectrophotometric) measurements. Thus, the FIA method has higher analytical sensitivity than the EIA method using absorption (optical density) measurement.
Chemiluminescence immunoassay: chemiluminescent immunoassays (CLIA) use a chemiluminescent label that produces light when excited by chemical energy; the emission is measured using a photodetector.
1. Validation of MYH6 mutations by Whole exome sequencing and Sanger sequencing
1.1 sample Collection
ASD families were collected at the national hospitals of the Guangdong province during the 11 th to 2018 th months from 2015. The diagnosis of ASD is confirmed by cardiac ultrasound, digital Subtraction Angiography (DSA), magnetic resonance imaging/angiography, or computed tomography. All parents underwent physical examination to confirm clinical performance.
The study was approved by the ethical committee of the people's hospital of Guangdong province. The patient or his parent sign informed consent.
1.2 Whole exome sequencing
1.2.1 extraction of DNA
The whole genome DNA of the peripheral blood of a patient and parents is extracted by using a blood genome DNA extraction kit of Tiangen, and the DNA is quantitatively detected by using 1 percent agarose gel electrophoresis and a Nanodrop 2000 spectrophotometer.
1.2.2 Whole exome sequencing and mutation Annotation
The genomic DNA was randomly fragmented into fragments of 200-300bp in length using a sonicator (Covaris 2, massachusetts, USA), 500ng of the purified DNA fragments were subjected to end repair and ligated with labeled linkers to construct a DNA sequencing library. The 3-step enzymatic reaction was performed according to the illumina standard library construction method: the sample library was formed by end repair, addition of "a" and ligation of Illumina sequencing adaptors (by PCR reaction, an 8bp barcode was ligated to the DNA fragment). Exon capture was performed using SureSelect Human All Exon V6+ UTR r2core design (91mb, agilent), the specific procedure is described in the instructions.
Sequencing was performed using the Illumina HiSeq X-tenstform platform, SNP sites and indel markers were detected using gattk v3.5, and annotation was performed using ANNOVAR.
The conservation and pathogenicity of candidate variations are predicted using bioinformatic prediction tools. All variants were screened for pathogenic variants against the public databases 1000 genes Project (http:// www. International genome. Org /), genome variant server, NHLBI GO Entity Sequencing Project (ESP) http:// EVS. Gs. Washington. Edu/EVS /) and genome Aggregation Consortium (ExAC) (http:// ExAC. Broadassociation. Org /).
1.2.3 Sanger sequencing validation
Mutation sites were verified using Sanger sequencing and Sanger sequencing was performed on an ABI3730 sequencer. MYH6 primer has nucleotide sequence shown as SEQ ID NO.4 and SEQ ID NO. 5.
1.3 results
The results are shown in FIG. 1:
(A) Both families carry the MYH6 p.E526K mutation, are autosomal dominant inheritance, and accord with complete cosegregation.
(B) In both families, patients carried the mutation, and neither member of the normal family carried the mutation.
(C) Conservation analysis, indicated by the arrow, the 526 site is highly conserved across species.
Whole exome sequencing results showed that the patient harbored the MYH6 gene variation NM — 002471c.g1576ap.e526k, while the normal member of the pedigree did not carry this mutation.
ATPase Activity detection
2.1 cell lines
C2C12 cell line
2.2 construction of vectors
The cDNA coding human MYH6 (1-780 AA) truncated MYH 6-WT and mutant MYH6780-E526K thereof are amplified by polymerase chain reaction and verified by DNA sequencing. These sequences were cloned into the vector GV362 (genechem) with 3Flag-tag at the XhoI/BamHI position.
2.3 transfection and determination of Mg2+ -atp enzyme Activity
Actin-activated Mg2+ -ATPase activity was measured spectrophotometrically at 37 ℃. C2C12 cells were transfected with MYH 6-WT and MYH 6-E780-526K, respectively. 48 hours after transfection, cells were collected and counted using a cytometer auto 1000 counter (nexcelom bioscience). Total ATPase activity was determined in a medium consisting of 50mmol Tris-HCl, pH 7.4, 120mmol NaCl, 20mmol KCl, 4mmol MgCl2, 240mmol sucrose, 1mmol potassium ethylenediaminetetraacetate (K + -TDNF), 3mMATP disodium and 104 cells (final volume of 1 ml). 1mmol of quinacrine was added to determine the activity of Mg2+ -ATPase. To 0.9mmol of sulfuric acid was added 2ml of a mixture of 1% lubrauol and 1% ammonium molybdate, and the reaction was stopped after 20 minutes. After development, the color was yellow and the wavelength was set to 390nm.
2.4 results
The results are shown in FIG. 2, with no significant difference between MYH6 780-WT and MYH 6-E526K (p > 0.05).
3. Myofilament assembly experiment
3.1 cell lines
C2C12 cell line
3.2 construction of adenovirus vectors
The full-length human MYH6 cDNA and its mutant p.E526K were amplified from IMAGE clone 14406689 (GenBank Accession number BC 132667.1) and cloned into the adenovirus vector GV138 (Genechem), respectively, with a 3Flag tag at the AgeI/NheI site. HEK293 cells were co-transfected with either the Ad-MYH6 WT or Ad-MYH6 p.E526K constructs and the packaging construct to generate adenoviruses.
3.3 transfection and visualization of cell morphology
Mouse C2C12 myoblasts were cultured in DulbCo Modified EGO Medium (DMEM) and 10% fetal bovine serum (FBS; invitrogen) was added. In the cell infection assay, the above cells were seeded on precoated glass coverslips in 12 well plates in DMEM containing 10% FBS. Cells were infected with AD-MYH6 WT and AD-MYH6 p.E526K, and then transferred into DMEM (containing 1% horse serum) as a differentiation medium to induce differentiation. After infection, the medium was changed daily. The cells were further cultured in differentiation medium for 7 days. On day 8, cells on the coverslips were fixed in 4% paraformaldehyde for 15 minutes, washed extensively with phosphate buffered saline, and finally transferred to slides. The cell morphology was observed using a laser scanning confocal microscope (leica TCS SP 5) at a magnification of 400x1.4.
3.4 results
3.4.1 morphological structures as shown in FIG. 3, they are classified into three categories according to the structural organization:
(A) Class I: normal bands, cells with clear striated myofibrils, align parallel to each other along the long axis of the cell.
(B) And II: mixed bands, cells containing a mixture of striated muscle fibrils and non-striated muscle fibers, wherein the striated muscle fibers are thin and misaligned.
(C) And (3) class III: no bands, cells containing bright fluorescent spots, lacking the characteristic tissue repeat unit characteristic of striated muscle myofibrils.
3.4.2 After wild type MYH6 and mutant E526K MYH6 are over-expressed in C2C12 cells, myofilament structure analysis and counting
Within the mutant group, the number of class III cells was significantly greater than in the wild type group.
From this, it was found that the researchers could administer drugs to the culture system when transfecting cells, and the therapeutic effect of the drugs on ASD could be judged from the morphological distribution of the cultured cell structure tissue.
It should be understood that the above-described embodiments are merely exemplary of the present invention, and are not intended to limit the present invention, and that any modification, equivalent replacement, or improvement made without departing from the spirit and principle of the present invention shall fall within the protection scope of the present invention.
A sequence table:
<110> institute of cardiovascular disease of Guangdong province
Application of <120> MYH6 gene in congenital heart disease diagnosis product
<160>5
<210>1
<211>26288
<212>DNA
<213> Artificial sequence
<220>
<223> -MYH6 Gene
<400>1
1 agatagagag actcctgcgg cccaggtaag aggaggtttg gggtgggatg ccctgcagcc
61 cgtccacaga gcccccaccg tgagggacct ccttcaccag gagtggggtg caggtcagtt
121 ggaggcctaa gggctctatt aaaactgcct atctccaggc ccagggaagt tccccctgac
181 acaaggaggt tccacaggaa acccagaaac ctcttttctc cttctctgac tctccatttc
241 tttctctgca tcattctgag tctcctacat gttgtctcca tctttccatc ttccttcctc
301 ctttggatgg cttccttccc ttgatcctgg ttttatcttg cctcttggtc ttcatcgaca
361 cttgtcacaa tcatgcttct ttgtctctct cccttgtcct tccttcttgg cacgtgttct
421 cacctccctg cctctctgct tctaaccctg tttccacacc ccgtccctcg cactcatatt
481 gactcggtgc cctttctttt ctgcctctgc gtctttccct ttctgactcc ctggtctgtc
541 ctgcctgtct gcgctctggg gctgcctcca tccccgggtg gcctgcctct gttgttcttc
601 actctcctca tctgttcttc tctctgcccg gctctacctc tgttgttcct tgctccaccc
661 acggtccaga ttcttcagga ttctccgtga agggataacc aggtgagaac tgcccccatt
721 ttctctgcag agactggggc atgcttctcc tgggagccgg attgctggac caggggtctg
781 ctgtcccaag cactcagcgc caacccttag catactccag ccaatgccac cccagggaaa
841 ccccttacag agattgtcct tcagcatcac ctcagagggc aggagaagca gagccctgag
901 taggggaggg tgcaacagca ggtgcctctc ccagggtgga ggagaggagc gggggtaggg
961 aggggggctg cagaggacaa agccactcgc tggagcctgg gctccctcag gagtaacata
1021 gccctcctgt ctctgaccca ggggaagcac caagatgacc gatgcccaga tggctgactt
1081 tggggcagcg gcccagtacc tccgcaagtc agagaaggag cgtctagagg cccagacccg
1141 gccctttgac attcgcactg agtgcttcgt gcccgatgac aaggaagagt ttgtcaaagc
1201 caagattttg tcccgggagg gaggcaaggt cattgctgaa accgagaatg ggaaggtgag
1261 tagggcatgg cgccggggca gaagggaagg aggtctggga aagaagatgc agaggtggag
1321 ccacttgcag ggggagctga gagggctgga gaaaagccaa ggccagtggg gatgccagga
1381 catgctcctt tgaggagccc agaatctgat ccctctcaaa ttgacctgag ctggtgcaac
1441 aggtgccacc cagggccatg ttccccctgc cagagaggat gctgaggaag aagaacctca
1501 gtgttcgcct aagaggggtc ttgtagataa agagggcaca gacacagcat taaatgatgc
1561 ccccttcttg cacttg/atatc cctcttccct gtgcctcagt ttcctccatg agtccacttt
1621 ctcaaattcc gttcacccaa atcaagagta attcttagac ccagatgaac acaaagatca
1681 gaaacttttg agctgagcac tctccttgac tggcactcag aagctctggt ccctggtttg
1741 ctcacaccag ccaagagaat cacccctggt taccagctgc ggctcagggc tgtgtgcctc
1801 atgaactcgt tgactgaatg ttacaaccca ttgaagtgta gaataacagg ccacaatccc
1861 ctggggcttt tgactctgat cccagctctg ccacccgcta gtcactgtgc aggcaaatca
1921 tttagtcatt tagagccacg gatttctcca ctataaaaaa cactggaata cctactggca
1981 ggatctaatg acatcagggc atggcaaact gactgctgcc aatcaaacca caccaacagt
2041 gatggatggg gagtgtggag tagatgggtg aactactttt ccagcagggg tgaaggtttg
2101 ccctgagcaa cagataccct aaagcgctgc ccgcgggaga cagcctcggg gtcagcataa
2161 ggtgtgcaca gatctgagag ctgccaatct ccaggtctgc cccaagaccc ttggaacata
2221 gggactgaag agtgatggtc atgggcacag ggtgtcccca ggatggtctg gggatctggc
2281 aagagaaagg taccctagga cagtctctag gatgggagat acaatgggaa gggaaattac
2341 ctggggaaag tgtcccaggg gacatcgggg taggggccgg ggcactggtc agagcaaggg
2401 gagcaaggcc aagtccctgt gtcctgggag gaggtcagtg ggcagtgctg gcaagggtcc
2461 cggagggatt gtggtcactc atcctcctgc ttatgcgccc cctccagacg gtgactgtga
2521 aggaggacca ggtgttgcag cagaacccac ccaagttcga caagattgag gacatggcca
2581 tgctgacctt cctgcacgag cccgcggtgc ttttcaacct caaggagcgc tacgcggcct
2641 ggatgatata tgtgagtggc tcctgcacac tgcagaggct tcctgtgctg cgtggaggcc
2701 taaataagcc aggggggctc tcccaagaag agggggagag actcccaagg gacccaagtc
2761 cccttccccc ctccacccct agtcagctgc aggaggagta gagccagctg gagtgaacag
2821 ggacatgcct ggctgccacc actgcctgtc ccaggctctc cccaccaacc tcatgcccag
2881 ccttgtctcc tgctccagac ctactcgggc ctcttctgtg tcactgtcaa cccctacaag
2941 tggctgccgg tgtacaatgc cgaggtggtg gccgcctacc ggggcaagaa gaggagtgag
3001 gccccgcccc acatcttctc catctccgac aacgcctatc agtacatgct gacaggtgag
3061 cctggtggcc cctggtctct gctcctcctc ccagacaccc acccagatcc tcagccctga
3121 ccccattgct tctcctcttt tttcttccag atcgggagaa ccagtccatc ctcatcacgt
3181 gagcgagtgc catcctccca cagaagggac tgggctgggg gcatacacgc tgatgcctag
3241 ggtgtagttg ggaggagagg tttaaggctg ggattgcagg gagcatgggg cactgagctc
3301 tcattagagg ggtgccagag caatgaacca tgtcaggcaa atcctgctgg gtgctgggct
3361 ctgatggcca ggctgggaag gggagcatgt gatgctgagc cctgtatgga gaacagtagg
3421 aatcctgagt tttgattggt ctctgtggcc cccaggggag aatccggggc ggggaagact
3481 gtgaacacca agcgtgtcat ccagtacttt gccagcattg cagccatagg tgaccgtggc
3541 aagaaggaca atgccaatgc gaacaaggtg ccatggggga cacaggctcg gcagaacagg
3601 ggttgggggg caggctgacc cgagttaccc ctaaccctcc cctccctgtg acgtggtggg
3661 gacagccaca ctgagctggg ctcccgatgg tcagcccagt atggaagacc ttcctgacag
3721 gagacactca ccctgaggtc tgggtaggat cctgtggagt cgcagaccca ctagcggttc
3781 acccagcccc gcacccccat tcctcagggc cagggcagcc tccctgccct ctcaccactg
3841 cctggaggtg gatggaggat gaacccatgc agttctgctc ctttcatagg gcaccctgga
3901 ggaccagatc atccaggcca accccgctct ggaggccttc ggcaatgcca agactgtccg
3961 gaacgacaac tcctcccgct ttgtgagtgc ctttgaccac tcccagtggc ctcatccagc
4021 cttgacaaga aaaagggggt gctgttttgc cacacccagt tgattgtact gtatctggct
4081 ttgggatatc aacatgcaca cgttggtggg aagagagcat aggctttgga gccaaaggtc
4141 tgactttcca cttgctcagc aagtccttac acctctctga gccctagttc cttcacctgt
4201 gaaacagggg gactaatatc caccctgcag attactggga ggattaggtg agatcatatg
4261 agaggtatga gcaggaggca ttctgtatgt gttcccctct gggccgaggt tccactagga
4321 ggtccctgca cagtgtgtga gggtggcatc ctctgcccgg cttcacttat actcaactga
4381 gacaccaaag aggtcgttta catttccaga accatccagg gcttctgggc tgaacagagg
4441 gccaggattt cactctgtcc ttcccgccag ttccctcact ctgtcccatt cgtccccagg
4501 ggaaattcat taggatccac tttggggcca ctggaaagct ggcttctgca gacatagaga
4561 cctgtgagta ccagcaggga ggctgccacc ctctaggtcc ccctctgcct tctctccctg
4621 cctggcggcc agtctcatca ttcctgccat ctcctgtttt gtctgcattt gcctctgggc
4681 tttaggatcc tttttattta agccacatct tctcgcctgg ccctcttcat caagctgtgg
4741 gtgccccctg ccctctgccc ccatggccac ctttttctgg ctctactctc tttccttcct
4801 cacctgcctt cctcccctcc acccacctca gacctgctgg agaagtcccg ggtgatcttc
4861 cagctgaaag ctgagagaaa ctaccacatc ttctaccaga ttctgtccaa caagaagccg
4921 gagttgctgg gtgaacctgc ctgccacccc ccacccactg ctgtccctgc tgcacacccc
4981 aacgactcct gcatgcaggg cagggccctc ctgctcccca ctgtgcccca ccttgctgct
5041 cacttccctt ctccctccac tcactccgcc agctccctct cgcttccctc ccaagaccac
5101 ctgcgtctcc tctcgcctcc ctgtgcagtc acacacctca ctccttctcc acccttctct
5161 ccactcctcc ctcggcttgt ctttgccttc tcctctttat ttgcctcccc atctcccatg
5221 tgtcactccc ctgccaccct ccctcctcct tgttactgga gcccctgcca gggcccctct
5281 tctacccttt cacttcctct gggttcactc cttggtcctt gctgacttct cttctctccc
5341 tgctccctgt cctcccttcc tccattcacc ccgtccctta cccctccctg cccctccctc
5401 cctttcccaa ctctacctgc cccttccctg ccctccgcct gcccccttgc ccctgcctca
5461 ccccttgcct ggtgcagaca tgctgctggt caccaacaat ccctacgact acgccttcgt
5521 gtctcaggga gaggtgtccg tggcctccat tgatgactcc gaggagctca tggccaccga
5581 tgtgagtgag ggggctgctg cggccgttcg agggacccca ggagctcctg gggccaccgc
5641 tccaaccccc ctctttgtct ctcgctctgt cccagagtgc ctttgacgtg ctgggcttca
5701 cttcagagga gaaagctggc gtctacaagc tgacgggagc catcatgcac tacgggaaca
5761 tgaagttcaa gcagaagcag cgggaggagc aggcggagcc agacggcacc gaaggtggga
5821 ggggcaggca ggcagccctg ggaaggcctg aggtgctgac caggctctct gcgggactca
5881 gatcccagag actctgaggc ttgtggggca gtggggtgtg ttgtgggatg gtgagggaca
5941 gggacgtggg agacgtgggc agacagagag tccaccacaa tcccaactcc tcaaccccag
6001 ctgcactcac cagaactgag gtggggaatt ttcctcctgt gcccaagact cccccagccc
6061 caggaagcac agcccctgag ctctgcacat caccatcact aatgcagggc ctttgcctgc
6121 ccagcccttg ggtaagcccc tcgtgggctc ataccatgtt gtttgggagg cagtgggcca
6181 ggggtcagga catagcccag ggcattggtg tgtcagtttc ctcctcagtg aaatggatca
6241 acaatctttc ctcactcctc tggtggctac tgtgaggtcc tttgagaaaa tgtgaaggtg
6301 caaacagtgc tagacaggtg cccaagaaca ttcctcccta ccttcaggga cccttctcca
6361 agtctgccca gatcaaagtg tcaagctggg gttcatgata acacaccaac agttattaca
6421 acattcttga aattacacca aataactcct cctctaaaca gagaaatacc catgttgggt
6481 ggcacatttg gatggctggg ggtaggagcg tggtactgtc tgatatactc tcagccagtc
6541 agattgggta acatgtggat ggagaagaca gcatggccag tccagggcta gacactgggg
6601 tagagaacga aggagacagg gagcagagga catctagccc ctcagccaca cccttgccct
6661 ggagaggcga gggatatggt gaaggtgggg atatgcccac agcagtgctt gtgaaagacc
6721 tgacccagag atgccacaga tgtagagaca gagctgagaa gagccagttg tggcaagagg
6781 ccatgggccg gataaggggg ctgtgctcca gcctgactca ggcacacgtt ggttgagtaa
6841 ccaaggcaag ccctgtgctc ttccaggcct tgatttcttc ctctttaagg aaaagaaatt
6901 ggacctgatg cttcctaaag tcttggcccc aggacaggga aggaggctca ctccctgaaa
6961 gtgttcactc aggccaggtg cagtggctca tgcctgtaat cccagcactt tgggaggcca
7021 aggcaggtgg atcacttgag gtaaggagtt tgagaccagc ctgggcaaca tggtgaaacc
7081 ctgtctctac tacagataca aaaattagcc tggcatggtg gctcatgtct gtagtcccag
7141 ctacttggga ggctgaggca ggaaaatcac ttgaacccag gaggtggagg ctgtagtgag
7201 ccaagatcgt gccactgcac tcaagcctgg gtgacagagc aagcctctat cttaaaaaaa
7261 aaaaaaggaa gtgctcactt atcctttccc tctcaaccag atgctgacaa gtcggcctac
7321 ctcatggggc tgaactcagc tgacctgctc aaggggctgt gccaccctcg ggtgaaagtg
7381 ggcaacgagt atgtcaccaa ggggcagagc gtgcagcagg tgtactactc catcggggct
7441 ctggccaagg cagtgtatga gaagatgttc aactggatgg tgacgcgcat caacgccacc
7501 ctggagacca agcagccacg ccagtacttc ataggagtcc tggacatcgc tggcttcgag
7561 atcttcgacg tgagttggga cccctgggag tgggagaaca atcactcgct tgctcctaca
7621 ttcaacagcc atttgctgag agccagctgt ggaccagaca tgggaaggca gtggggactg
7681 tgtggtgaca gaggcagtca ttgtccctgt cttcagggga agccctcctc cactgccctg
7741 acatggaggg gacagccata ccctgctggg ctcggcacag tgcacgggca cagccccaat
7801 ggccactcac acccactttc tgactgctcc cacccctcat gccccctgca gttcaacagc
7861 tttgagcagc tctgcatcaa cttcaccaac gagaagctgc agcagttctt caaccaccac
7921 atgttcgtgc tggagcagga ggagtacaag aaggagggca ttgagtggac attcattgac
7981 tttggcatgg acctgcaggc ctgcattgac ctcatcgaga aggtgcctcc ttggcctcac
8041 cacctatgcc ccctcctctg ccatccagac aaagtggtgg ctgagtccct tctacaccca
8101 agaaactaga gtcccaagaa tcccaggcct ttctccaggc ccagcttctc cccactgtga
8161 agtcatgggc atgaacagga tgatcccccc actcttcctt tcccaggacc ttgcacttta
8221 tgcccctttg tggtggtccc ctcagtgtct taagagtgag atgtagtgaa ggagaggccc
8281 ctggcccctc tgaccgccca tgagaagcgt cattcatgga aagatcctag gctgaaatta
8341 gagatgtttg gcctcccacc accttcctgt tggttgagaa ataagccagt ctccagccct
8401 cttgcttatg ggcattcctc agaagagaca aggccgcagg cgggaggccc cataggctgg
8461 ggctgacttg ctctcagtga acctctgctc tttgtcagca taggccagag cccggattgt
8521 ctgacccaca cccagcccag ccacggcctt catgaaatgg gagcttcccc acatgctttg
8581 ggtcattatc cagattctta accagagttc tcatgtttca gagccctcag aatgccataa
8641 aactgtgtgt ggaaaaaagc atgtgtacat tcatacatac atgtgtgtgc ttgtgcatgt
8701 gtgtgtgtgt acgtgtgtgt gtgtacatgc gtttttctgg agagacagtc tttagcttca
8761 acaaattctt aaaaggattc ctgccccaag aaaaatcaag aaccaccagg tttttggaag
8821 tgcagagtgt ggtaaagaac ctggatcctt ctatctaacc cttgaagaat tgctactggt
8881 gtcatacaga cagagcctgg cccggtgcct ctgacacaca tctgtccctg ccctcctgcc
8941 cctggggcag tgagccatca gagagaaggg gctgtgctgt gaggcactgt gggccttgtg
9001 gggggtgatt aggagtgcat gactctttgt tggacccact gggcagaaag gaggaggaag
9061 gggcttttta aattccagga atattggctt cctgttttag ggtaagaggt accagcacag
9121 cgccccttca gcaggccagc gctactggct ccagattcct tttcctgtca gggtatggga
9181 ctgtggaagc ctgggagtgt gctcagtgat tctctctttg cctcttcacc ctgccctcag
9241 cccatgggca tcatgtccat cctggaggag gagtgcatgt tccccaaggc cactgacatg
9301 accttcaagg ccaagctgta cgacaaccac ctgggcaagt ccaacaattt ccagaagcca
9361 cgcaacatca aggggaagca ggaagcccac ttctccctga tccactacgc cggcactgtg
9421 gactacaaca tcctgggctg gctggaaaaa aacaaggatc ctctcaacga gactgttgtg
9481 gccctgtacc agaagtcctc cctcaagctc atggccactc tcttctcctc ctacgcaact
9541 gccgatactg gtaagcaggc agcccctgca ctgggccagg ggacttctga agacacaaag
9601 ggccagggtc ctgctgcttc aaagcacatg actccatagg caggcacagg ggagcccatg
9661 agtcaagcca cctcctggct cacctcacca cagtccagct gggcttctgt agcacctgcc
9721 gttctccact ttgtgttatg agtgttgata tagctgtctc atgtttcctc aagatgggga
9781 gtaactggag gtcagtgagg gtggcacatg catccctgta ccatgcccag cagggaacga
9841 tgcatgtggg agttctcaac aaatgttgag aggacactga acaaaagagc ctccagttca
9901 gaaaaggaag agaaaggatg tggcttgaaa tgaagaggat aaagtgtaag aagaaaagta
9961 gaggttgggc acggtggctc acgcctgtaa tcccagcact ttgggaggcc gaggcgggtg
10021 gatcacaagg tcaggagttc gagaccagtc tggtcaacat ggtgaaaccc cgtctctact
10081 aaaaatacaa aaattagcct ggcgtggtgg cacctgcctg tagtcccagc cacttgggag
10141 gctgaggcag gaaagttgct tgaatccggg cgacggaggt tgcagtgagc caagattgca
10201 ccactgcact ccagcatggg tgacagagtg agattccatc tcaaaaatag aaggaagaag
10261 aagaagaaga agaagaagaa gaagaagaag aagaagaaga agaagaagaa gaagaagaag
10321 aagaagaaga agaagaagaa gaagaggagg aggaggagga ggaggagaac tagaatgtgg
10381 aaagatataa gaaggaaggg caagtagagg gagagctaag ggcactgatg tatgtcagtg
10441 cctactatgg gcaagcacca gtgagctgcc ctacaggcgt ggtcttatct aatcctcttt
10501 acaactttgg gaagttgtta ctgtcatcct catggtaaac tgaatcttgg agaattcctt
10561 gcccaaagtc tcagagctac caagcgagca gcagagctct gcctctgccc aagggctcct
10621 ttattttcca gctcctgttg attatttctc ctctcgctgt ttaggggaca gtggtaaaag
10681 caaaggaggc aagaaaaagg gctcatcctt ccagacggtg tcggctctcc accgggtaag
10741 aagggcccag gggtgccagg acacctggtg gaatggccca gcccagagac ttctggctgc
10801 accacctatt ctgatgcttg agtttgatga ggaaagaagc tagggctacg tagtcgtttt
10861 ttagtgtgta gattccacaa aagcctgaac tcacgtcaca aattatgtgg cagcccctgt
10921 ccctttgatg attctggtgg agagtgtctg gggaccaggg tttaagggcc taagggatgg
10981 tccttgtggc tcctaactcc ccaccttcat ctgcctccag gaaaatctca acaagctaat
11041 gaccaacctg aggaccaccc atcctcactt tgtgcgttgc atcatcccca atgagcggaa
11101 ggctccaggt gagccaggag aagaccttag tctggggagg acagctggca tccactttac
11161 cctaaggctg accctttccc cttccctcct gacacagggg tgatggacaa ccccctggtc
11221 atgcaccagc tgcgctgcaa tggcgtgctg gagggcatcc gcatctgcag gaagggcttc
11281 cccaaccgca tcctctacgg ggacttccgg cagaggtggg tatgagggtg ccccagagct
11341 catagaacag ggggagccag gctgccctga tgggaatggg atctgcaggt gaccctggaa
11401 ttctgtgggc agagcagatc actgcagagc atgggtgact ctggacactt ccctcctcag
11461 gtatcgcatc ctgaacccag tggccatccc tgagggacag ttcattgata gcaggaaggg
11521 gacagagaag ctgctcagct ctctggacat tgatcacaac cagtacaagt ttggccacac
11581 caaggtgagt ctagagcccc actgggtggt tgcagggcag gtggccatgt tgagtggagc
11641 agagaggagt ttaggaggca gaagcctaat tctggcttcc ttatcaacct tatcaagggc
11701 tgaaacccag gcttcattcc ggtcttgttt gtcaaatttt tactcttact tctagaaggc
11761 atggggtgat gggtcacctg ggagctcatc cagggtcttc caccctggat actcccctct
11821 gaggctgcgg cctgttgcat ctaccccttg cctgcaggtg ttcttcaagg cagggctgct
11881 tgggctgctg gaggagatgc gggatgagag gctgagccgc atcatcacgc gcatgcaggc
11941 ccaagcccgg ggccagctca tgcgcattga gttcaagaag atagtggaac gcaggtgaga
12001 caggaggaaa agggaggcat gcactagaga tgtagaggca gatccgcaat gtcaactagt
12061 gtgggtcaga agacctgggt tcagacctac cagctggcct gggcaagtta ctttaccact
12121 tcgaatctca ttgcaaattc ttcttcttct tcttcttctt cttttttttt ttttaaagaa
12181 acttctctat aggaaaatgc aaattaagac accaatgaaa taccatttta aaacactaga
12241 ctttgcttgc tcagatggtc tacaaatttt aaaaaatgaa agaaacaagt agataaaaat
12301 aaaatgaaag gaaaaataat ttttaaaagt tttaaaaatc actagactga caaaaattaa
12361 gaagcctgac ccactgctta cagatgtgta aattagtgca acttcctagg aaaacagttt
12421 atcactatct tttaaagttg aacagctgca ggccaggcgc ggtggctcat gcctgaaatc
12481 ccagcacttt gggaggccga ggcgggtgga tcacgaggtc aggagatcaa aaccatcctg
12541 gctaacatgg tgaaacccca tctctactaa aaaaatacaa aaaattagcc gggtgtggtg
12601 gcagatgcct gtagtcccag ctactctgga ggctgaggca ggagaatggc atgagcccgg
12661 gaggcagagc ttgcagtgag ccaagatcga gccactgcac tctagcctgg gcgacagagc
12721 gagactccat ctcaaaaaaa aaaaagttga acagctgcat acttctccat tccactcctg
12781 agtacattcc tacagagaaa ctcttataca tgtacaccat gacatgaaaa ataatctttt
12841 agcagcattg gtcataatag caaagatctt aaaacaactt gaatttccat ccacagggga
12901 atgggtaaat agtattacag tcattcagtg gaatattata aaacagtgaa aagatgtgaa
12961 ctccaactac atgatacaat atgtttgaac attaaagcat attgttagta aacaaaggca
13021 aatcttggaa ggatacatac agtatgatgc aatttttata aagctcataa ataatcaaaa
13081 ccagccattc attgtttaaa gatacataca tatggctggg cacagtggct tatgcctgta
13141 accccagcac tttgggaggc taaggcaggc ggatcacctg aggtcaggag atggagacca
13201 gcctggccaa catggtgaaa ccccgtctct actaaaacta caaaaattag ctgggcatgg
13261 tggcaggcac ctgtaattcc agctactcag gagctgaggc aggagaatcg cttgaatccg
13321 ggtggcagag gttgcagtga gccgagattg tgccattgca ctccagcctg ggcaacaaga
13381 gtgaaactcc atctcaaaat aaataaagta aaataaaaat aaagatacat tcatatgtgg
13441 ttaaagtaat ttttgaaaaa gcaaggaaag gaaaaataag attcagagtg gcggctgctc
13501 ctggcggggt gacaggggtg taggaaggaa cgcacaggta gatcaatggc tggtaacatt
13561 tcagctcctg tttcagtggt aggttcatgg atagtcattt tgctttcatg ctgcataact
13621 tacatactta ttatagacat tcttatatgt aaacccctac ataattttta acatatttga
13681 agttcttatg agaatagaaa aaccaaacag agtagacatt ctataagtgg tagtttccat
13741 taccactaat atcccagctg ggaggatata aactgccctt tcatcaaatt gattaataaa
13801 tatttatcaa gcaactccat gttcagtgta gtgatgttgg aggtgggtgt gcacaagaag
13861 gaagtctacg tgcctacgaa cttgcttagt agggcccatg attgggaagc tctcttttat
13921 agtgccccac cctgcctcca cgtttccttg ccagggatgc cctgctggta atccagtgga
13981 acattcgggc cttcatgggg gtcaagaatt ggccctggat gaagctctac ttcaagatca
14041 agccgctgct gaagagcgca gagacggaga aggagatggc caccatgaag gaagagttcg
14101 ggcgcatcaa agagacgctg gagaagtccg aggctcgccg caaggagctg gaggagaaga
14161 tggtgtccct gctgcaggag aagaatgacc tgcagctcca agtgcaggcg gtgaggccac
14221 gtgattatct cttcagccct ctcctcccct cccctagatt atagcccatc tcacaaccag
14281 ggactgggag tctaggagtg ccagctcttt ttaagaccct aggtctcctc tctttaacca
14341 tcagcttcct ccctgttctc ttctcccagg aacaagacaa cctcaatgat gctgaggagc
14401 gctgcgacca gctgatcaaa aacaagattc agctggaggc caaagtaaag gagatgaatg
14461 agaggctgga ggatgaggag gagatgaacg cggagctcac tgccaagaag cgcaagctgg
14521 aagacgagtg ctcagagctc aagaaggaca ttgatgacct ggagctgaca ctggccaagg
14581 tggagaagga gaagcatgca acagagaaca aggtgagggc agctccctct ggcttcagcc
14641 caggtctcct caagactccc agactagagt gttgtcctgg tccttggcat ggaggtcccc
14701 atagatgtct ccaggctggt gatctttgac cctaaagggg atgggttttt ggtcggcagg
14761 tgaagaacct aacagaggag atggctgggc tggatgaaat catcgctaag ctgaccaagg
14821 agaagaaagc tctacaagag gcccatcagc aggccctgga tgaccttcag gttgaggaag
14881 acaaggtcaa cagcctgtcc aagtctaagg tcaagctgga gcagcaggtg gatgatgtga
14941 gtagtaagaa ccatgctcct gctctcagag caagattttg caggcaacac caatggccca
15001 gaaagtcctg atccctagaa ttaacttcta tggcccctga agcttttttg ctctctgtag
15061 ttcctcacta cagtaggtct ctgaatcctt tgtgcttgca ggatttctct gttggtttga
15121 cttccaatcc cactggactt caagtttaga aggaggcaaa agagcataca ctatggattt
15181 catgttttcc acactttgct tattttcttc cctccaacag ctggagggat ccctagagca
15241 agagaagaag gtgcgcatgg acctggagcg agcaaagcgg aaactggagg gcgacctgaa
15301 gctgacccag gagagcatca tggacctgga aaatgataaa ctgcagctgg aagaaaagct
15361 taagaagtag gagactgtgg tggccaggag gggctaatgg aggtgtctgg cctggtagat
15421 agagtgcagg gtgctgcgcc tccactggcc acagttgcct tgggtatgct gggaataagg
15481 tcaatcacag ccctcttccg ccactttctg ggctggcgag gggaggggga ggtgccgatt
15541 ctggcatact aaggccaaga agagaatgag ccccagagga aggaaggcta cctgtcactc
15601 ccccaccccc acccttctcc tgcaggaagg agtttgacat taatcagcag aacagtaaga
15661 ttgaggatga gcaggtgctg gcccttcaac tacagaagaa actgaaggaa aaccaggtga
15721 ctttttttcc cagtgcatga aagtgggagc tcaatagccc tgaggtaact gaggctgcag
15781 cagctgctta gggttctaca caatatctgg aactccaggc agcctcatag acccaaccat
15841 ccctgactta caggcgctca ggaacactag ccttccccca tagagcaaga atacattacg
15901 ttagcaaaac tgtttgagaa gggggactca tacctactaa agggcttctc cttctgagat
15961 ctgctctgcc tcagggactt tctactctaa gacaaatgat agagctctat tctcctctaa
16021 cccttcctct ggtagttcag ccctctgaac gcagggtgaa aaaaaaaaaa ggcttcaagg
16081 agcaccttcc tgtgagctgc tctgttcata ttcttcccgg tactaacccc agccactaac
16141 ccaggctgag tccccatagg gcactcatga taagagccaa ttccaacaac tgtgagcaag
16201 tcacttaccc tccctgatcc tcagattctc ttctcacctg taaaatgaga ctgacaatac
16261 ctaccacaca ggaccagagg ggataatgta tttgaaacca ttttgtcaac taggaaattc
16321 tatacaagta tcatattaat atagcccaat ttagagaagt cagccagcca ctagcctaag
16381 aaggtattgt tttgtcttct caatggcctt ctcattcctc tgcagctcaa gatttagtga
16441 acagccatag tctcccttag ctttaatgaa cctcaaaccc taatgtgctt ttagtatcgg
16501 gtttgtcaga agagacctgg aagtccactg ccatccccat tatagagcta cagaagctac
16561 atggccaggt ctggacatag tgaccccaag ggcaacagga actcggctac tggggcggga
16621 ccttgtcctc tcactttggg gcagactgtg gctggtagaa agaggtagtc tcccctctgc
16681 acttgaggcc catggcccag gctgcaagta atgtatgaac acaattccac tcctctgggg
16741 ctgcacaggg actggcccgc cttcattagt aatttgccct cccatcttct tggatgcccc
16801 ttctgggttt tagctagaat atcgggccat cctcaggttc ttctacccta ggtctgggca
16861 acttgtttgg cctcttggac acagaataac agtcctgtta gtctcatcag ctctcggcaa
16921 taggctatgg ctcctccttc atccccaaga tcttgctcag aagtcccacc ttctccatcc
16981 tgggagcaga ggcatggtgg tcctctctgc tgcttgtagg acccatccat gaacagtcca
17041 ttaaagctgt ccataacccg aggtgaaggg atttccactg aacccccgtt ttgctcctgg
17101 ctagccagac aacagatcaa aatggtagat acgatattct cccaatttag tcaagaccaa
17161 ggctaaggcc caaaaaatga ggtaagggca cttaaagagg ataaggagat gaggtgaaga
17221 ggagagtagc ctgctagcac tttcctggcc tggaagggag caatcatgtt gaaacccagc
17281 cctgggcata aacacagcaa gcctgggaga gcaaggaata tggttgattg gactttgtgg
17341 ttaacttgga gaattgcaaa ggtatctgat tgtttcgagg catgttgtca caaatatttg
17401 taaaatacaa gcactcattt tcccgtctta tgaatagcgc aacagagcct agtgaatctg
17461 gggactctga acttcttgat ctcacaggat accaggatcc cccttcaacc acaggttctc
17521 aggatttggg gctgcagatg ctcacactgg gtctgagatg cccttgggag cttcagccaa
17581 attcctattg atggcctatg cattatagga tgtttagtag catccctggc ccctaccctc
17641 tagatgccag tagcaagccc caccaagaca tgacaatcag acattgccaa ctgttccctg
17701 gggcacaaaa ttgcccctag ttgagaacca ctgcttgaga ggaacctaag ttcctggtag
17761 cttttcagag ccggggggat tccagtggag gggtccaggc ggtgggtctg agccctttgt
17821 gtctgaccca ggcacgcatc gaggagctgg aggaggagct ggaggccgag cgcaccgcca
17881 gggctaaggt ggagaagctg cgctcagacc tgtctcggga gctggaggag atcagcgagc
17941 ggctggaaga ggccggcggg gccacgtccg tgcagatcga gatgaacaag aagcgcgagg
18001 ccgagttcca gaagatgcgg cgggacctgg aggaggccac gctgcagcac gaggccactg
18061 ccgcggccct gcgcaagaag cacgccgaca gcgtggccga gctgggcgag cagatcgaca
18121 acctgcagcg ggtgaagcag aagctggaga aggagaagag cgagttcaag ctggagctgg
18181 atgacgtcac ctccaacatg gagcagatca tcaaggccaa ggcaggctct gctcggcctc
18241 ccctcgccct ctcccctgca cagcggagcc tcccccatgc cttctctctc tgtctgccat
18301 ctcccttgtc attctcattc tcttcatcac cctttggtct ctcttcctgt ctcccctgcc
18361 cctctctggc tctcctcacc ctctctatct cttcatgttc ctcctttctt taattcaagt
18421 ctctcttcag actgcgccct cccacacctt ctgtgtcccc ctcctgccct ctggcattcc
18481 ccatctctga ccctctcttc cttcctctgg tcgactcagc ccctcccaca ctcacccttc
18541 ctgtcttgct tcctgaaggc aaacctggag aaagtgtctc ggacgctgga ggaccaggcc
18601 aatgagtacc gcgtgaagct agaagaggcc caacgctccc tcaatgattt caccacccag
18661 cgagccaagc tgcagaccga gaatggtggg tgcccctaac caaccccctg cctagggcag
18721 gacatgactt gtgaaatggc ccacaagccc ctcatttcac ctccaggaga gttggcccgg
18781 cagctagagg aaaaggaggc gctaatctcg cagctgaccc gggggaagct ctcttatacc
18841 cagcaaatgg aggacctcaa aaggcagctg gaggaggagg gcaaggtgag gcccagtggg
18901 gagggtgggc aggcttgatg gcagccctgg ggcaattcat ctcagtgcca gaaatggagc
18961 ctggagctgg aaagagtcct ctgcaaggga aagaccctcc agtctaggtt ctgccctgca
19021 gctaagcgtc atttaatgcc tcttttctta ttcgtaaggg gatggggtga gcagactggg
19081 aaactcctca aacagtgagg tgccacatca gcccacatgg tgaataaggc tgggcttggt
19141 tgaagtacta cataagaaga gaatctagag aatggggcac agggagtccc tcccacctcc
19201 tggtgccccc ccccctcccc aggcgaagaa cgccctggcc catgcactgc agtcggcccg
19261 gcatgactgc gacctgctgc gggagcagta cgaggaggag acagaggcca aggccgagct
19321 gcagcgcgtc ctgtccaagg ccaactcgga ggtggcccag tggaggacca agtatgagac
19381 ggacgccatt cagcggactg aggagctcga agaggccaag tgagctccag ataccccctt
19441 aacctgactc tcagagagga aggggcgaga ggacctgggg tggggacagg caaagtggtc
19501 atgagacgga agtggaagag acaggaggaa ctcggagggc aacagaagtg cttggaagaa
19561 agcctgaact ctttgctctg tgaactctgg ctggccctga cccacttcct gtgacgggcg
19621 agcttttggc ccgggttata cctgatgctc acgtataaga cgagcaaaaa gcttgttggt
19681 cagaggagct accgtcgatc agcctgtgtg gggggtgagg gcagggggca ctgacaccca
19741 gatgccactg caggtaggga ggacgcctgg gcagcccgtg ctggcggact ctgttccagg
19801 catgagcagg ctcagctcct gctaggctgg acttacggtg tctcaaggag atatagggag
19861 ggggtggaag gaggtccacc caaggctcca gtgttgccca gtagagtcac acacacaccc
19921 tccaccctca cctgggcaga aagaagctgg cccagcggct gcaggatgcc gaggaggccg
19981 tggaggctgt taatgccaag tgctcctcac tggagaagac caagcaccgg ctacagaatg
20041 agatagagga cttgatggtg gacgtagagc gctccaatgc tgctgctgca gccctggaca
20101 agaagcagag aaactttgac aaggtggacc atgggcgggg gccgcagcca gcatgcaggg
20161 caagggggca tgaggggttc agtgagaggc caaaggcaac ctccttggag gtggaggagg
20221 agggctaagc ccaggctcgg gaccagggac agatcttgga catgcggctg aggctggggg
20281 ctggggcact gggaagcagg agggctgggg agctaaggct ggggggctga agagtgagcc
20341 ttgtccccgg gcagatcctg gccgagtgga agcagaagta tgaggagtcg cagtctgagc
20401 tggagtcctc acagaaggag gctcgctccc tcagcacaga gctcttcaag ctcaagaacg
20461 cctacgagga gtccctggag cacctagaga ccttcaagcg ggagaacaag aaccttcagg
20521 gtgtgctggg ggtccaagag gccagagatg agttggtggg agggagggcc atgcaggggc
20581 agggggaaca taggctttga gctttctggc cctctggtcc ccagaggaaa tctcggacct
20641 tactgagcag ctaggagaag gaggaaagaa tgtgcatgag ctggagaagg tccgcaaaca
20701 gctggaggtg gagaagctgg agctgcagtc agccctggag gaggcagagg tgagggccga
20761 gaactccctg caccccatcc ctgttctgcc gctgtctccc acttctccct cacctggggg
20821 tgaccctgac cccaggacaa aatctattca ttccatattc tttgttcaac attatctacc
20881 cactattcac tacccatgac tgcctccaaa gccaaggtct gcacaaagga aaatgtcagt
20941 ctgattagag gccaaaggtt ttgtttccca ccaggtttta aaagttggaa tctggccata
21001 ataataacca cttagacagt gggtaggagt gtggggttcc agagtcaaac aggcctgagt
21061 tggaacacag cttgaggact ttcactgcag cgttgggcaa aatctttaat ctctctctgc
21121 ctcagttttc tcatctgtaa aatggaatta actgtacata cctcatatga ttttacacat
21181 gattattata aagattaaat gaggtaacac atttaagcac ttaatatata ttagctattg
21241 ttactcttca tttctaagca cctgggaata gccctgagtt ttctgggctt ctaacttttc
21301 tcaggaaagg gtgagggacc tggaaaacaa gataaaattt tgtatttgtg gttataaaaa
21361 ttcctccatt ttctataata ctttagacag gtcaggaatt tatgcagtgt tagtgctgga
21421 gggtctggca attgtgaggt ccaaaccctt ttcttgacag gggaagccca gagagtccag
21481 cactttctcc ccaatagcac cgtggtgggc atggggtgca gatcccacct ccccatctct
21541 tctcagctct tcttctctgg gcgatagtcc tggctgacac cgtgtatctt ctcatcctcc
21601 ctctcaaccc tgccctgtgc cctgtctgcc cgccctcgcc ccaccccttc ccaggcctcc
21661 ctggagcacg aggagggcaa gatcctccgg gcccagctag agttcaacca gatcaaggca
21721 gagatcgagc ggaagctggc agagaaggac gaggagatgg aacaggccaa gcgcaaccac
21781 cagcgggtgg tggactcgct gcagacctcc ctggatgcag agacacgcag ccgcaacgag
21841 gtcctgaggg tgaagaagaa gatggaagga gacctcaatg agatggagat ccagctcagc
21901 cacgccaacc gcatggctgc cgaggcccag aagcaagtca agagcctcca gagcttgctg
21961 aaggtacatg ggggcgggag gtcccctcag gggactggcc tccatgtggc ctggagaagc
22021 agtggtgtct ggatacaggc accagattcc tcctgcccct gggttactgc agggacctct
22081 gacaggtgcc ctcagtgaag ggcaccgagg ctggcttctg ctcacaccca ctctcctgat
22141 gctcaggaca cccagatcca gctggacgat gcggtccgtg ccaacgacga cctgaaggag
22201 aacatcgcca tcgtggagcg gcgcaacaac ctgctgcagg ctgagctgga ggagctgcgt
22261 gccgtggtgg agcagacaga gcggtcccgg aagctggcgg agcaggagct gattgagacc
22321 agcgagcggg tgcagctgct gcattcccag gtgagggggt caggagccac cttgtggaaa
22381 cctactgagt gcagagccca ggacatctag aaaagccaga tgttctaagt gagcacatct
22441 agccagggtc acaaatcatt tcctctctta ggccaactct catctgtggt ggctgcagaa
22501 ccattatatt aagaaagcgg tctctactta gaagctaaga gggtcatgat tgattgctga
22561 tacctgccaa agccacaaat ctgggagtag tggaatgtat cctgttattt gatattcttg
22621 atctgaaaga cagcctccgg cttgctctgt aaagatgaga gtttgggagt ttaaagaagc
22681 ataactgcat ctcttgcaaa ccaagctggc tagaacacca ttttctgcaa tcccacccac
22741 actgttttca gttatactct gcaatgagac tttgtgctca ccttttgcag tgccctgtgg
22801 agttttgttc tttaatctag tatgtgtgag aatgacatca tccacttacc tcatcccctc
22861 ttccttaccc cactacattc ttggtatagc tataaacatc tctggaatat tgtcctggta
22921 aaaagttgtt tccatcttcc ttggaatatt gtcatgctcc tacgtaaaca tgttgctaaa
22981 gagctccagg gtaatactgc agaccttttg ctatttgaag tcttttttca gagtttagta
23041 atcttagata caatgtctag aatgtatgca ctttcatagg aaaagggaaa gcaggtacaa
23101 aacgatcaat agtctaaaag tgggcttgtt gttttaaaaa aaaaatgacc acctttaatt
23161 ctttctggag aaagggtatg aaatcaggta acaaagtgta gtatatattt gatcattttt
23221 ctctctccat gtctagaaca ccagcctcat caaccagaag aagaagatgg agtcggatct
23281 gacccagctc cagtcggaag tggaggaggc agtgcaggag tgcagaaacg ccgaggagaa
23341 ggccaagaag gccatcacgg atgtaagtga ccgcccacct tccgcctccc ctaaagacag
23401 aaacaaggcc ttgggtccag gccaggccac tgtgctgtaa caccaagcca actctgcagt
23461 tctgtggatt tgagggcctg atgggagaaa ggagatcctt ggggggcaaa aggccccggc
23521 ccctggccca tgttccttgc cacctctctc ctgcacacag gccgccatga tggcagagga
23581 gctgaagaag gagcaggaca ccagcgccca cctggagcgc atgaagaaga acatggagca
23641 gaccattaag gacctgcagc accggctgga cgaggccgag cagatcgccc tcaagggagg
23701 caagaagcag ctgcagaagc tggaagcgcg ggtgcgggag ctggagggtg agctggaggc
23761 cgagcagaag cgcaacgcag agtcggtgaa gggcatgagg aagagcgagc ggcgcatcaa
23821 ggagctcacc taccaggtgc ggcggacgcc agacaccagg agtagatgtg gaagtttctt
23881 ctctggcccc actgccccgc cctcacaggg ctcctctcac ctcctccttg agatgctgtt
23941 ggtagattta acgttcttct cacgctctgc agtcagtttg acttgagtct atgagttttt
24001 ccagcaaatg aagaatctac ttctacttcc tgaaaactct tctaactagt ctttccccag
24061 gtttctttct ttcttttttt ttttttttaa taactctaag tgctaccatg aagacttcag
24121 aacagttcaa agaatccttc caccttcgac tgtggggata agagtcaggg gaggggaaaa
24181 gacccggaaa tcttccatag aacttctggc acacaaagag aaggccacag agaaagagga
24241 ccctagaatg ctctaaaacc tccacttgca tagctgagag ctgtgccctt ggcccgttat
24301 tttcagtgta cctgggaaga aaaggccaag gagacgaggg tgtcagtcca tttgatagat
24361 ggataccaga ggcacaagaa agaggttaca gatacagaac cacagagtga tttgtggaca
24421 gaagtagaaa tggcatcctg gcacatacaa tgataaagag ataggaatga tcgagtgacg
24481 ttggagccag tgatcccgat gcctgaattc tggcccagta caatatatta gaatgtagaa
24541 taatctggat tatgataata cccccttctt tctgcattct ttttctggtc aagaactact
24601 ggccaagaga acctatgtaa gtccaggttg gagctttatc caccatactg gagctggaac
24661 agacctggtg cttttatatt accacattag ggaattccat taggttctga gcccctcccc
24721 ctacttctag ctttatgact tcagccttca ttgctctgtg gatccctgac tgacaacctt
24781 gcattgcccc tttgacctac gatagagtca gagaatcttc cccaccacct ctttgacctg
24841 gatcattgca gggaggggca gcaaaggcaa ggggagaaga gtaaaatgat ggaggaggga
24901 aaggtgattg catttgctcc ccctccaaac cagcttctcc caccctccca cccccagaca
24961 gaggaagaca aaaagaacct gctgcggcta caggacctgg tggacaagct gcaactgaag
25021 gtcaaggcct acaagcgcca ggccgaggag gcggtgagtt cagagctttc ttccctttct
25081 catcaacaca cctactattt gtgagaacca atgaatatct cctacagagg ggcctggaca
25141 aagagtttgc tataaacttt aactctcaaa catttgtttg acacatctgg tatgctcaga
25201 gctgtcaggt gttctgaatt aacaaaggca ccacctacaa gctgcttaca attcagatac
25261 cataacccaa cagaaggcag tgtagatgct agtgcaggac gtggggcagc cgaagctgaa
25321 ggcaggaagg tggcggtgga attgggccta gaaggggacc cagctagcca cagggcagtg
25381 gggaagacat ctgggtggat gtgagttgct gattagcatg cctgcacagg aagctggggt
25441 ccgggacagg tgcagcaaaa caggattctg aaggggccca gatcgggcag catgggattt
25501 gtctggggca gtggatggcc gtgaaggact ctgagtgctg gacatgtttg agaagagtgc
25561 aaggcagttg caggataccc ttgggaaggc tgttgcagga atatgcatga ggtatgggtg
25621 cctcagggac agggagctgg aacctcaggt tgagaggctg agaatcccat agcccatctc
25681 cagctcattc acccatcccc actgtcccac cacaggagga gcaagccaac accaacctgt
25741 ccaagttccg caaggtgcag catgagctgg atgaggcaga ggagcgggcg gacatcgctg
25801 agtcccaggt caacaagctt cgagccaaga gccgtgacat tggtgccaag gtgggtccct
25861 cccctgggct tcactagtca cttccacatt agcatgcccc ctgatatggg tgcccttcag
25921 agtgggcact gcttgcccta tatgtaggca gttctgaggg tcccatagct tacataacct
25981 gagaatccac tctcctgctc aaaacagccc cccactgact ggaacttctg cagagatccc
26041 cagttccatc cccctaaacc acaagtgcct ctaacgtggg accacaggat ccctggggcc
26101 ctgcctctcc ctccaagggc atctccctta ggcctctgaa agccccaggg atttgtcccc
26161 acacacttct ccctcttgcc agctgccccc tcacacctct tattcttttt gcagcaaaaa
26221 atgcacgatg aggagtgaca ctgcctcggg aacctcactc ttgccaacct gtaataaata
26281 tgagtgcc
<210>2
<211>1939
<212>PRT
<213> Artificial sequence
<220>
<223> -MYH6 Gene expression product protein
<400>2
1 MTDAQMADFG AAAQYLRKSE KERLEAQTRP FDIRTECFVP DDKEEFVKAK ILSREGGKVI
61 AETENGKTVT VKEDQVLQQN PPKFDKIEDM AMLTFLHEPA VLFNLKERYA AWMIYTYSGL
121 FCVTVNPYKW LPVYNAEVVA AYRGKKRSEA PPHIFSISDN AYQYMLTDRE NQSILITGES
181 GAGKTVNTKR VIQYFASIAA IGDRGKKDNA NANKGTLEDQ IIQANPALEA FGNAKTVRND
241 NSSRFGKFIR IHFGATGKLA SADIETYLLE KSRVIFQLKA ERNYHIFYQI LSNKKPELLD
301 MLLVTNNPYD YAFVSQGEVS VASIDDSEEL MATDSAFDVL GFTSEEKAGV YKLTGAIMHY
361 GNMKFKQKQR EEQAEPDGTE DADKSAYLMG LNSADLLKGL CHPRVKVGNE YVTKGQSVQQ
421 VYYSIGALAK AVYEKMFNWM VTRINATLET KQPRQYFIGV LDIAGFEIFD FNSFEQLCIN
481 FTNEKLQQFF NHHMFVLEQE EYKKEGIEWT FIDFGMDLQA CIDLIE/KKPMG IMSILEEECM
541 FPKATDMTFK AKLYDNHLGK SNNFQKPRNI KGKQEAHFSL IHYAGTVDYN ILGWLEKNKD
601 PLNETVVALY QKSSLKLMAT LFSSYATADT GDSGKSKGGK KKGSSFQTVS ALHRENLNKL
661 MTNLRTTHPH FVRCIIPNER KAPGVMDNPL VMHQLRCNGV LEGIRICRKG FPNRILYGDF
721 RQRYRILNPV AIPEGQFIDS RKGTEKLLSS LDIDHNQYKF GHTKVFFKAG LLGLLEEMRD
781 ERLSRIITRM QAQARGQLMR IEFKKIVERR DALLVIQWNI RAFMGVKNWP WMKLYFKIKP
841 LLKSAETEKE MATMKEEFGR IKETLEKSEA RRKELEEKMV SLLQEKNDLQ LQVQAEQDNL
901 NDAEERCDQL IKNKIQLEAK VKEMNERLED EEEMNAELTA KKRKLEDECS ELKKDIDDLE
961 LTLAKVEKEK HATENKVKNL TEEMAGLDEI IAKLTKEKKA LQEAHQQALD DLQVEEDKVN
1021 SLSKSKVKLE QQVDDLEGSL EQEKKVRMDL ERAKRKLEGD LKLTQESIMD LENDKLQLEE
1081 KLKKKEFDIN QQNSKIEDEQ VLALQLQKKL KENQARIEEL EEELEAERTA RAKVEKLRSD
1141 LSRELEEISE RLEEAGGATS VQIEMNKKRE AEFQKMRRDL EEATLQHEAT AAALRKKHAD
1201 SVAELGEQID NLQRVKQKLE KEKSEFKLEL DDVTSNMEQI IKAKANLEKV SRTLEDQANE
1261 YRVKLEEAQR SLNDFTTQRA KLQTENGELA RQLEEKEALI SQLTRGKLSY TQQMEDLKRQ
1321 LEEEGKAKNA LAHALQSARH DCDLLREQYE EETEAKAELQ RVLSKANSEV AQWRTKYETD
1381 AIQRTEELEE AKKKLAQRLQ DAEEAVEAVN AKCSSLEKTK HRLQNEIEDL MVDVERSNAA
1441 AAALDKKQRN FDKILAEWKQ KYEESQSELE SSQKEARSLS TELFKLKNAY EESLEHLETF
1501 KRENKNLQEE ISDLTEQLGE GGKNVHELEK VRKQLEVEKL ELQSALEEAE ASLEHEEGKI
1561 LRAQLEFNQI KAEIERKLAE KDEEMEQAKR NHQRVVDSLQ TSLDAETRSR NEVLRVKKKM
1621 EGDLNEMEIQ LSHANRMAAE AQKQVKSLQS LLKDTQIQLD DAVRANDDLK ENIAIVERRN
1681 NLLQAELEEL RAVVEQTERS RKLAEQELIE TSERVQLLHS QNTSLINQKK KMESDLTQLQ
1741 SEVEEAVQEC RNAEEKAKKA ITDAAMMAEE LKKEQDTSAH LERMKKNMEQ TIKDLQHRLD
1801 EAEQIALKGG KKQLQKLEAR VRELEGELEA EQKRNAESVK GMRKSERRIK ELTYQTEEDK
1861 KNLLRLQDLV DKLQLKVKAY KRQAEEAEEQ ANTNLSKFRK VQHELDEAEE RADIAESQVN
1921 KLRAKSRDIG AKQKMHDEE
<210>3
<211>20
<212>DNA
<213> Artificial sequence
<220>
<223> detection Probe
<400>3
cttctcgatgaggtcaatgc
<210>4
<211>20
<212>DNA
<213> Artificial sequence
<220>
<224> -DIP 2C Gene-specific amplification primer 1
<400>4
caacagccatttgctgagag
<210>5
<211>20
<212>DNA
<213> Artificial sequence
<220>
<224> -DIP 2C Gene-specific amplification primer 2
<400>5
ctctagtttcttgggtgtag
Claims (5)
1. The application of a reagent for detecting mutation of a MYH6 mutant gene or a MYH6 gene expression product in preparing a congenital heart disease detection product; the product comprises a reagent for detecting mutation of a MYH6 mutant gene or a MYH6 gene expression product; the detection method of the product is at least one of direct nucleic acid sequencing, nucleic acid hybridization, nucleic acid amplification, nucleic acid probe or immunodetection; the product comprises a preparation, a chip or a kit; the nucleotide sequence of the MYH6 mutant gene is shown in SEQ ID NO.1, and the nucleotide sequence has a mutation from G to A at position 1576; the amino acid sequence of the mutation of the MYH6 gene expression product is shown in SEQ ID NO.2, and the amino acid sequence has a mutation from Glu to Lys at position 526.
2. The use according to claim 1, wherein the test sample of the product is peripheral blood.
3. The use according to claim 2, wherein the detection reagent is a probe having a nucleotide sequence shown as SEQ ID No. 3.
4. The use according to claim 1, wherein primers having the nucleotide sequences shown in SEQ ID No.4 and SEQ ID No.5 are used in the nucleic acid amplification.
5. A method for constructing a congenital heart disease model, which is characterized in that a reagent for expressing a MYH6 mutant gene is applied to a culture system, wherein the culture system is selected from a cell system, a tissue system or an organ system, the nucleotide sequence of the MYH6 mutant gene is shown in SEQ ID NO.1, and the nucleotide has a mutation from G to A at position 1576; the reagent for expressing the MYH6 mutant gene is MYH6 adenovirus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910735518.2A CN111073972B (en) | 2019-08-09 | 2019-08-09 | Application of MYH6 gene in congenital heart disease diagnosis product |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910735518.2A CN111073972B (en) | 2019-08-09 | 2019-08-09 | Application of MYH6 gene in congenital heart disease diagnosis product |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111073972A CN111073972A (en) | 2020-04-28 |
CN111073972B true CN111073972B (en) | 2023-04-11 |
Family
ID=70310139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910735518.2A Active CN111073972B (en) | 2019-08-09 | 2019-08-09 | Application of MYH6 gene in congenital heart disease diagnosis product |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111073972B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115873862A (en) * | 2022-11-24 | 2023-03-31 | 百世诺(北京)医疗科技有限公司 | Hypertrophic cardiomyopathy variant gene MYH7 and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109880895A (en) * | 2019-01-30 | 2019-06-14 | 中国人民解放军总医院 | A kind of probe groups and its application |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103374627B (en) * | 2012-04-27 | 2015-08-05 | 中国科学院上海生命科学研究院 | Associated Gene of Congenital Heart Disease PKD1L1 and application thereof |
CN103374625B (en) * | 2012-04-27 | 2016-04-13 | 中国科学院上海生命科学研究院 | Associated Gene of Congenital Heart Disease DLC1 and application thereof |
CN103374628B (en) * | 2012-04-27 | 2016-08-17 | 中国科学院上海生命科学研究院 | Associated Gene of Congenital Heart Disease FAM71A and application thereof |
EP3259594A4 (en) * | 2015-02-20 | 2018-12-26 | The Johns Hopkins University | Biomarkers of myocardial injury |
CN108300722A (en) * | 2018-02-11 | 2018-07-20 | 南京市妇幼保健院 | Gene panel for detecting congenital heart disease and application |
-
2019
- 2019-08-09 CN CN201910735518.2A patent/CN111073972B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109880895A (en) * | 2019-01-30 | 2019-06-14 | 中国人民解放军总医院 | A kind of probe groups and its application |
Also Published As
Publication number | Publication date |
---|---|
CN111073972A (en) | 2020-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109790583B (en) | Methods for typing lung adenocarcinoma subtypes | |
AU2019200670B2 (en) | Interrogatory cell-based assays and uses thereof | |
KR101323574B1 (en) | Method for measuring resistance or sensitivity to docetaxel | |
KR102657306B1 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
US20030175736A1 (en) | Expression profile of prostate cancer | |
US20040146907A1 (en) | Methods and compositions for detecting dysplasia | |
AU2018210695A1 (en) | Molecular subtyping, prognosis, and treatment of bladder cancer | |
KR20110020853A (en) | Methods of diagnosing rejection of a kidney allograft using genomic or proteomic expression profiling | |
BRPI0616090A2 (en) | methods and materials for identifying the origin of a carcinoma of unknown primary origin | |
KR20160117606A (en) | Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer | |
US20230390280A1 (en) | Biomarkers for the diagnosis and treatment of fibrotic lung disease | |
KR20140140069A (en) | Compositions and methods for diagnosis and treatment of pervasive developmental disorder | |
BR112016025627B1 (en) | USE OF THE COMBINATION OF SNX10 AND GBP1, METHOD FOR DIAGNOSING TUBERCULOSIS IN AN INDIVIDUAL AND DEVICE FOR USE IN THE SAME | |
US20040219579A1 (en) | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer | |
CN101111768A (en) | Lung cancer prognostics | |
WO2021183218A1 (en) | Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes | |
CA2504903A1 (en) | Method for identifying risk of melanoma and treatments thereof | |
KR102031858B1 (en) | composition for detecting senescence, kit containing the same and method of detecting the same | |
CN111073972B (en) | Application of MYH6 gene in congenital heart disease diagnosis product | |
KR101883936B1 (en) | Marker for predicting lymph node metastasis and method for predicting lymph node metastasis using the same | |
CN101784674A (en) | Predictive markers for EGFR inhibitors treatment | |
KR101683961B1 (en) | Recurrence Marker for Diagnosis of Bladder Cancer | |
US11104950B2 (en) | Human blood molecular biodosimeter panel for distinguishing radiation exposure from inflammation stress | |
KR102480128B1 (en) | Single nucleotide polymorphisms associated with immunity of African indicine breeds and their application | |
KR20070112564A (en) | Composition for diagnosing or treating imatinib resistant diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |